Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Lung Cancer

  Free Subscription


1 Am J Clin Oncol
1 Am J Pathol
1 Ann Oncol
2 Ann Surg Oncol
1 Ann Thorac Surg
1 Arch Bronconeumol
2 BMC Cancer
1 Br J Cancer
2 Cancer
1 Cancer Lett
1 Chest
7 Clin Lung Cancer
1 Clin Nucl Med
2 Eur J Cancer
2 Eur J Cardiothorac Surg
6 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
2 J Clin Oncol
1 J Nucl Med
3 J Thorac Cardiovasc Surg
13 J Thorac Oncol
3 JAMA Oncol
3 Lung Cancer
1 Oncogene
1 PLoS One
1 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Oncol

  1. YANG L, Lu X, Luo J, Huang D, et al
    Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
    Am J Clin Oncol. 2023 Nov 20. doi: 10.1097/COC.0000000000001066.
    PubMed         Abstract available

    Am J Pathol

  2. LAMI K, Ota N, Yamaoka S, Bychkov A, et al
    Standardized Classification of Lung Adenocarcinoma Subtypes and Improvement of Grading Assessment Through Deep Learning.
    Am J Pathol. 2023;193:2066-2079.
    PubMed         Abstract available

    Ann Oncol

  3. TRAN HT, Heeke S, Sujit S, Vokes N, et al
    Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer.
    Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023.
    PubMed         Abstract available

    Ann Surg Oncol

  4. MACHADO PFA, Pimenta S, Garcia AL, Nogueira T, et al
    ASO Visual Abstract: Effect of Preoperative Home-Based Exercise Training on Quality of Life After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
    Ann Surg Oncol. 2023 Nov 17. doi: 10.1245/s10434-023-14602.

  5. MACHADO PFA, Oliveiros B, Martins RA, Cruz J, et al
    ASO Author Reflections: Impact of a Preoperative Home-Based Exercise Program on Quality of Life After Lung Cancer Resection.
    Ann Surg Oncol. 2023 Nov 19. doi: 10.1245/s10434-023-14620.

    Ann Thorac Surg

  6. COLLINS ML, Mack SJ, Whitehorn GL, Till BM, et al
    Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States.
    Ann Thorac Surg. 2023 Nov 21:S0003-4975(23)01165.
    PubMed         Abstract available

    Arch Bronconeumol

  7. ESTEBAN V, Javaloyes J, Martinez-Lopez S, Sancho-Chust JN, et al
    Alveolar Macrophage Expression Differs According to Lung Cancer Subtype.
    Arch Bronconeumol. 2023 Nov 9:S0300-2896(23)00363.

    BMC Cancer

  8. LI S, Wang W, Yu H, Zhang S, et al
    Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    BMC Cancer. 2023;23:1115.
    PubMed         Abstract available

  9. JIN S, Liu T, Wang W, Li T, et al
    Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis.
    BMC Cancer. 2023;23:1125.
    PubMed         Abstract available

    Br J Cancer

  10. ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al
    Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
    Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491.
    PubMed         Abstract available


  11. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.

  12. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.

    Cancer Lett

  13. KONG R, Wei W, Man Q, Chen L, et al
    Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
    Cancer Lett. 2023;578:216442.
    PubMed         Abstract available


  14. ZHANG Y, Liang H, Cheng J, Choudhry AA, et al
    Associations between Sex-Specific Reproductive factors and Risk of New-Onset Lung Cancer Among Women.
    Chest. 2023 Nov 15:S0012-3692(23)05709-4. doi: 10.1016/j.chest.2023.
    PubMed         Abstract available

    Clin Lung Cancer

  15. GROSS AJ, Sheikh S, Kharouta M, Chaung K, et al
    The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series.
    Clin Lung Cancer. 2023;24:696-705.
    PubMed         Abstract available

  16. NAKAMICHI S, Kubota K, Matsuyama K, Misumi T, et al
    A Phase ? Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
    Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00186.
    PubMed         Abstract available

  17. PIRZADEH M, Lagina M, Wood C, Valley T, et al
    Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.
    Clin Lung Cancer. 2023 Oct 31:S1525-7304(23)00226.
    PubMed         Abstract available

  18. QIN A, Wells L, Malhotra B, Gadgeel S, et al
    A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Oct 26:S1525-7304(23)00224.
    PubMed         Abstract available

  19. VISONA G, Spiller LM, Hahn S, Hattingen E, et al
    Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers.
    Clin Lung Cancer. 2023;24:e311-e322.
    PubMed         Abstract available

  20. FARIA N, Lacerda C, Lopes J, Viana C, et al
    PET-CT SUV(max) and Endobronchial Ultrasound Features for Prediction of Malignancy: A Prospective Study.
    Clin Lung Cancer. 2023;24:753-760.
    PubMed         Abstract available

  21. LI S, Chen M, Wang Y, Li X, et al
    An Effective Malignancy Prediction Model for Incidentally Detected Pulmonary Subsolid Nodules Based on Current and Prior CT Scans.
    Clin Lung Cancer. 2023;24:e301-e310.
    PubMed         Abstract available

    Clin Nucl Med

  22. TAO Z, Qiu Y, Huang W, Wang A, et al
    Small Cell Carcinoma of the Ureter With Early Recurrence and Multiple Metastases Shown on 18F-FDG PET/CT.
    Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004828.
    PubMed         Abstract available

    Eur J Cancer

  23. RATAIN MJ, Strohbehn GW
    Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
    Eur J Cancer. 2023;194:113349.
    PubMed         Abstract available

  24. WENG PC, Huang YL, Cheng CY
    Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
    Eur J Cancer. 2023;196:113432.

    Eur J Cardiothorac Surg

  25. WANG MM, Li JQ, Dou SH, Li HJ, et al
    Lack of Incremental Value of Three-Dimensional Measurement in Assessing Invasiveness for Lung Cancer.
    Eur J Cardiothorac Surg. 2023 Nov 17:ezad373. doi: 10.1093.
    PubMed         Abstract available

  26. ZHANG M, Liu X, Ge M
    Prevalence and anatomical characteristics of medial-basal segment in right lung.
    Eur J Cardiothorac Surg. 2023;64:ezad342.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  27. SAFAVI AH, Palma DA, Giuliani ME
    Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?
    Int J Radiat Oncol Biol Phys. 2023;117:1232-1235.

  28. SIVA S, Staehler M
    The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
    Int J Radiat Oncol Biol Phys. 2023;117:1047.

  29. RAMESH S, Cifci A, Javeri S, Minne R, et al
    MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 16:S0360-3016(23)08139.
    PubMed         Abstract available

  30. AHN J, Yeghiaian-Alvandi R, Hegi-Johnson F, Browne LH, et al
    SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
    Int J Radiat Oncol Biol Phys. 2023;117:1213-1221.
    PubMed         Abstract available

  31. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2023;117:1222-1231.
    PubMed         Abstract available

  32. LEE SH, Geng H, Arnold J, Caruana R, et al
    Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;117:1270-1286.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  33. ZHANG J, Song L, Li G, Liang A, et al
    Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
    J Cancer Res Clin Oncol. 2023;149:17199-17213.
    PubMed         Abstract available

  34. XU M, Hao Y, Shi Z, Song Z, et al
    Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490.
    PubMed         Abstract available

    J Clin Oncol

  35. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
    Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
    J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
    PubMed         Abstract available

  36. RUDIN CM, Liu SV, Soo RA, Lu S, et al
    SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
    PubMed         Abstract available

    J Nucl Med

  37. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  38. DYAS AR, Bronsert MR, Stuart CM, Thomas MB, et al
    Analyzing the Impact of the COVID-19 Pandemic on Initial Oncologic Presentation and Treatment of Non-Small Cell Lung Cancer in the United States.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01098.
    PubMed         Abstract available

  39. SULLIVAN KA, Farrokhyar F, Patel YS, Liberman M, et al
    Preoperative Mediastinal Staging in Early-Stage Lung Cancer: Targeted Nodal Sampling is Not Inferior to Systematic Nodal Sampling.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01096.
    PubMed         Abstract available

  40. Discussion to: Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)00979.

    J Thorac Oncol

  41. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    PubMed         Abstract available

  42. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    PubMed         Abstract available

  43. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    PubMed         Abstract available

  44. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.

  45. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.

  46. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.

  47. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.

  48. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    PubMed         Abstract available

  49. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    PubMed         Abstract available

  50. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    PubMed         Abstract available

  51. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    PubMed         Abstract available

  52. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    PubMed         Abstract available

  53. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    PubMed         Abstract available

    JAMA Oncol

  54. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.

  55. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    PubMed         Abstract available

  56. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    PubMed         Abstract available

    Lung Cancer

  57. LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al
    Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report.
    Lung Cancer. 2023;186:107424.
    PubMed         Abstract available

  58. SAKATA Y, Saito G, Sakata S, Oya Y, et al
    Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
    Lung Cancer. 2023;186:107426.
    PubMed         Abstract available

  59. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
    Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
    Lung Cancer. 2023;186:107422.
    PubMed         Abstract available


  60. SUN X, Dai Y, He J, Li H, et al
    D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.
    Oncogene. 2023;42:3503-3513.
    PubMed         Abstract available

    PLoS One

  61. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed         Abstract available


  62. LI Y, Chen W, Xie F, Huang R, et al
    Novel electromagnetic navigation bronchoscopy system for the diagnosis of peripheral pulmonary nodules: a prospective, multicentre study.
    Thorax. 2023;78:1197-1205.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.